Teal Omics

Executive Summary

Teal Omics, operating as Teal Rise, is a San Francisco-based biotechnology company that leverages a proprietary proteogenomic dataset and organ-specific aging clocks to transform complex multi-omics data into actionable biological insights. Founded in 2021 from Stanford University research, the company's platform analyzes blood-based protein signatures to quantify organ aging and resilience, enabling accelerated research, clearer disease biology, and the development of next-generation diagnostics and therapeutics. By focusing on the intersection of aging and multi-omics, Teal Omics aims to address the growing demand for precision medicine tools that can predict and monitor age-related diseases at an early stage. The company's technology has the potential to revolutionize drug development and clinical diagnostics by providing a non-invasive, blood-based method to assess organ-specific health. With the aging population and rising prevalence of chronic diseases, Teal Omics is well-positioned to capture significant market share. The company's strong academic roots and focus on proteogenomic data differentiation set it apart from competitors. As Teal Omics progresses toward commercialization, its success will depend on validating its platform in clinical settings and securing partnerships with pharmaceutical firms and healthcare providers.

Upcoming Catalysts (preview)

• Q3 2026Publication of organ aging clock validation study in a peer-reviewed journal70% success
• Q4 2026Strategic partnership with a top pharmaceutical company for drug development applications50% success
• Q2 2026Series A funding round closure to support commercialization efforts80% success